Table 6.
American College of Rheumatology (ACR) criteria scores of 20, 50, and 70 network meta-analysis base case results for combination treatments in DMARD-experienced patients: licensed ETN combination versus other licensed biologic DMARD combination
| Treatment | Control | Fixed effects OR v control (95% CrI) | Random effects OR v control (95% CrI) |
|---|---|---|---|
| ACR 20 | |||
| ETN 2 × 25 mg/week + DMARD | ABA 10 mg/kg/4 weeks + DMARD | 2.715 (1.521, 4.956)‡ | 2.858 (1.306, 6.815)‡ |
| ETN 2 × 25 mg/week + DMARD | ADA 40 mg/2 weeks + DMARD | 2.53 (1.405, 4.742)‡ | 2.72 (1.235, 6.357)‡ |
| ETN 2 × 25 mg/week + DMARD | CZP 200 mg/2 weeks + DMARD | 0.836 (0.437, 1.613) | 0.846 (0.341, 2.173) |
| ETN 2 × 25 mg/week + DMARD | GOL 50 mg/4 weeks + DMARD | 2.546 (1.235, 5.249)‡ | 2.759 (1.066, 7.88)‡ |
| ETN 2 × 25 mg/week + DMARD | INF 3 mg/kg/8 weeks + DMARD | 2.651 (1.509, 4.791)‡ | 2.786 (1.299, 6.301)‡ |
| ETN 2 × 25 mg/week + DMARD | RTX 2 × 1000 mg + DMARD | 2.48 (1.278, 4.958)‡ | 2.521 (0.966, 6.711) |
| ETN 2 × 25 mg/week + DMARD | TOC 8 mg/kg/4 weeks + DMARD | 1.987 (1.115, 3.602)‡ | 2.121 (0.959, 5.107) |
| ACR 50 | |||
| ETN 2 × 25 mg/week + DMARD | ABA 10 mg/kg/4 weeks + DMARD | 2.871 (1.395, 6.523)‡ | 3.07 (1.161, 8.969)‡ |
| ETN 2 × 25 mg/week + DMARD | ADA 40 mg/2 weeks + DMARD | 2.625 (1.249, 6.101)‡ | 2.882 (1.082, 8.347)‡ |
| ETN 2 × 25 mg/week + DMARD | CZP 200 mg/2 weeks + DMARD | 1.144 (0.492, 2.847)‡ | 1.143 (0.358, 3.715) |
| ETN 2 × 25 mg/week + DMARD | GOL 50 mg/4 weeks + DMARD | 2.264 (0.924, 5.999)‡ | 2.277 (0.672, 7.943) |
| ETN 2 × 25 mg/week + DMARD | INF 3 mg/kg/8 weeks + DMARD | 2.896 (1.426, 6.583)‡ | 3.098 (1.186, 8.671)‡ |
| ETN 2 × 25 mg/week + DMARD | RTX 2 × 1000 mg + DMARD | 2.662 (1.109, 6.817)‡ | 2.714 (0.826, 9.174) |
| ETN 2 × 25 mg/week + DMARD | TOC 8 mg/kg/4 weeks + DMARD | 1.759 (0.849, 4.018) | 2.068 (0.766, 6.284) |
| ACR 70† | |||
| ETN 2 × 25 mg/week + DMARD | ABA 10 mg/kg/4 weeks + DMARD | 5.405 (1.348, 39.22)‡ | 5.278 (1.016, 46.3)‡ |
| ETN 2 × 25 mg/week + DMARD | ADA 40 mg/2 weeks + DMARD | 4.826 (1.171, 34.53)‡ | 5.45 (1.07, 45.914)‡ |
| ETN 2 × 25 mg/week + DMARD | CZP 200 mg/2 weeks + DMARD | 1.661 (0.329, 13.06) | 1.636 (0.244, 14.84) |
| ETN 2 × 25 mg/week + DMARD | GOL 50 mg/4 weeks + DMARD | 4.055 (0.796, 31.279) | 4.312 (0.604, 48.757) |
| ETN 2 × 25 mg/week + DMARD | INF 3 mg/kg/8 weeks + DMARD | 5.395 (1.358, 38.16)‡ | 5.642 (1.126, 48.13)‡ |
| ETN 2 × 25 mg/week + DMARD | RTX 2 × 1000 mg + DMARD | 7.924 (1.686, 59.453)‡ | 8.058 (1.225, 78.37)‡ |
| ETN 2 × 25 mg/week + DMARD | TOC 8 mg/kg/4 weeks + DMARD | 2.385 (0.593, 16.28) | 2.766 (0.535, 25.2) |
Notes:
ACR 70 data with continuity correction;
licensed ETN combination has significantly higher odds of ACR outcome compared to other licensed biologic DMARD combination (based on the 95% CrI).
Abbreviations: ABA, abatacept; ADA, adalimumab; ANA, anakinra; CrI, credible interval (Bayesian probability interval); CZP, certolizumab pegol; DMARD, disease-modifying antirheumatic drug (MTX or SUL); ETN, etanercept; exp, experienced; GOL, golimumab; INF, infliximab; MTX, methotrexate; OR, odds ratio; RTX, rituximab; SUL, sulfasalazine; TOC, tocilizumab.